Eurofins debuts 2 combined tests for COVID/influenza, RSV

By staff writers

December 1, 2021 -- Eurofins Technologies has launched two new reverse transcription polymerase chain reaction (RT-PCR) tests for the simultaneous detection of SARS-CoV-2, influenza A/B, or respiratory syncytial virus (RSV).

The new multiplex kits have been granted the CE Mark and are designed to detect and differentiate three viral infections in the same PCR run, Eurofins said.

The first test, the Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR assay, differentiates between influenza A, B, and SARS-CoV-2. The test can simultaneously detect two SARS-CoV-2 targets (N and RdRP gene) as recommended by the World Health Organization, the company noted.

The second test, the RSV A, RSV B RT-PCR assay, differentiates between the RSV subtypes A and B.

Eurofins lands $30M COVID diagnostic testing contract
Eurofins Genomics has won a $30 million contract with the U.S. Department of Air Force and the U.S. Department of Health and Human Services to build...
Eurofins to acquire DNA Diagnostics Center
Eurofins Scientific plans to acquire DNA Diagnostics Center, according to the latter firm. The deal will help Eurofins expand into the markets for consumer...
Eurofins unit gets U.S. contract for expanded COVID testing
The Clinical Enterprises subsidiary of Eurofins Scientific has been awarded an agreement by the U.S. government to expand COVID-19 testing across the...
Eurofins debuts new SARS-CoV-2 variant assay
Eurofins has launched a new SARS-CoV-2 assay and increased its capacity to detect and monitor new variants of the novel coronavirus.
Eurofins debuts pooled COVID-19 PCR test
Eurofins Clinical Diagnostics announced that its pooled polymerase chain reaction (PCR) SARS-CoV-2 detection test will be available at U.S. labs, including...

Copyright © 2021

Last Updated ka 12/1/2021 9:20:55 AM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current